-
Atorvastatin Workflows for Vascular and Ferroptosis Research
2026-08-14
Atorvastatin is a versatile HMG-CoA reductase inhibitor for connecting cholesterol-pathway perturbation with vascular phenotypes, endoplasmic reticulum stress, and ferroptosis-related cancer biology. This practical guide provides formulation guidance, assay workflows, quantitative starting points, and troubleshooting strategies for cardiovascular and hepatocellular carcinoma models.
-
Multianimal MRI for Pancreatic Tumor Monitoring
2026-08-14
Kempinska and colleagues present a four-chamber MRI workflow that images up to four pancreatic cancer-bearing mice in one acquisition, improving the efficiency of tumor detection and longitudinal measurement in KPC models. The protocol also provides a practical framework for evaluating gemcitabine treatment response while clarifying how anatomical imaging should be combined with mechanistic and pathological endpoints.
-
Hyperthermia–Cisplatin Activates Caspase-8
2026-08-13
The 2024 study identifies a mechanistic link between hyperthermia, cisplatin, and caspase-8 stabilization through CUL3-regulated K63-linked polyubiquitination and p62 interaction. This caspase-8-centered pathway enhanced both caspase-3-associated apoptosis and gasdermin-linked pyroptosis, providing a rationale for measuring caspase-8 activity alongside complementary cell-death assays.
-
Moxidectin–Polyenes Synergy in Oral Candidiasis
2026-08-13
A 2024 study showed that Moxidectin enhances amphotericin B and nystatin activity against Candida albicans by increasing fungal ergosterol biosynthesis and polyene binding. Transcriptomic, mutant, biochemical, and mouse-model data support a target-complementary combination strategy, while clinical translation remains unestablished.
-
Separating Growth Arrest from Cancer Cell Death
2026-08-12
Hannah Schwartz’s dissertation argues that in vitro anti-cancer drug testing should distinguish relative viability from fractional viability because these measures combine or resolve different biological outcomes. Its central implication is practical: drug-response studies need time-aware, parallel measurements of proliferation and cell killing to avoid treating growth inhibition as a direct proxy for cytotoxicity.
-
Resazurin Cell Viability Assay for Wnt Studies
2026-08-12
Learn how the Resazurin Cell Viability Assay Kit can strengthen Wnt and skeletal disease experiments by separating metabolic viability signals from differentiation and pathway effects. This guide translates findings from a sclerosteosis study into practical assay design, controls, and interpretation strategies.
-
Difloxacin HCl: A Mechanism-First Assay Guide
2026-08-11
Difloxacin HCl is a quinolone antimicrobial antibiotic with value in antimicrobial susceptibility testing and multidrug resistance research. This mechanism-first guide explains how to separate bacterial DNA replication inhibition, MRP substrate sensitization, and mitotic checkpoint biology without overextending the evidence.
-
SNAI1, EMT, and Stemness in Thymic Tumors
2026-08-11
A 2024 study identifies SNAI1 as a transcriptional hub that promotes epithelial–mesenchymal transition and preserves cancer stem cell-like properties in thymic epithelial tumors. Integrated genomic, single-cell, epigenomic, proteomic, and functional assays connect SNAI1 to a PIK3R2/p-EphA2/GSK3β/β-catenin signaling axis, suggesting a mechanistic framework for therapeutic investigation.
-
DrPISA Expands Thermal Proteomics to Insoluble Targets
2026-08-10
DrPISA combines deep eutectic solvent-assisted solubilization with reverse PISA to profile heat-aggregated proteins that conventional soluble-fraction assays can miss. The study shows improved protein recovery, enhanced sensitivity to subtle stability changes, reduced mass-spectrometry demands, and expanded target discovery in a celastrol application.
-
EZ Cap™ Mouse IL-12 mRNA (m1Ψ): Assays
2026-08-09
EZ Cap™ Mouse IL-12 mRNA (m1Ψ) combines mouse IL-12 coding capacity with Cap 1, m1Ψ, and poly(A) design. This guide explains how to separate transcript quality, delivery performance, and immune biology when building rigorous cytokine mRNA assays.
-
5-(N,N-dimethyl)-Amiloride in Endothelial Assays
2026-08-08
Explore how 5-(N,N-dimethyl)-Amiloride hydrochloride can serve as a mechanistic perturbation tool in endothelial barrier research, connecting Na+/H+ exchange with moesin-associated injury in sepsis models without overstating current evidence.
-
ABT-737 and the Apoptotic Logic of Cell Stress
2026-08-07
ABT-737 is a mechanistically defined BCL-2 protein inhibitor that exposes how mitochondrial apoptotic priming can be studied alongside emerging RNA Pol II stress biology. This thought-leadership guide translates those insights into assay design, biomarker strategy, and translational decision-making across lymphoma, multiple myeloma, small-cell lung cancer, and acute myeloid leukemia research.
-
PreScission Protease (PSP): Technical Guidance for Tag Cleav
2026-08-07
PreScission Protease (PSP) addresses the need for precise, low-temperature cleavage of fusion protein tags, such as GST, during protein purification. It is optimal for workflows requiring high specificity at the Gln-Gly bond, but should not be used outside its defined substrate sequence or recommended buffer and storage conditions.
-
Ferroptosis Gene Signature and Atorvastatin in HCC Prognosis
2026-08-06
This study introduces a novel four-gene ferroptosis-related prognostic model for hepatocellular carcinoma (HCC) and identifies atorvastatin as a potential agent that induces ferroptosis in HCC cells. The findings advance prognostic stratification and support experimental designs targeting ferroptosis modulation in liver cancer.
-
Cy3 Goat Anti-Human IgG (H+L) Antibody: Workflow Mastery
2026-08-06
Unlock high-sensitivity, multiplexed immunodetection across ICC, IHC, flow cytometry, and ELISA with the Cy3 Goat Anti-Human IgG (H+L) Antibody. This guide distills advanced experimental strategies, protocol optimizations, and troubleshooting insights for translational research needs.